Intrinsic Value of S&P & Nasdaq Contact Us

Adaptive Biotechnologies Corporation ADPT NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
54/100
4/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$21.25
+46.2%

Adaptive Biotechnologies Corporation (ADPT) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Seattle, WA, United States. The current CEO is Chad Robins.

ADPT has IPO date of 2019-06-27, 619 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $2.24B.

About Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

📍 1165 Eastlake Avenue East, Seattle, WA 98109 📞 206 659 0067
Company Details
SectorHealthcare
IndustryBiotechnology
CountryUnited States
ExchangeNASDAQ Global Select
CurrencyUSD
IPO Date2019-06-27
CEOChad Robins
Employees619
Trading Info
Current Price$14.53
Market Cap$2.24B
52-Week Range6.706-20.76
Beta2.30
ETFNo
ADRNo
CUSIP00650F109
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message